Hummingbird Bioscience Licenses Novel Antibodies to Immunome Jan 7, 2025 08:00AM
Immunome Inc. (IMNM) Appoints Phil Tsai as CTO Jun 27, 2024 08:03AM
Immunome Appoints Phil Tsai as Chief Technical Officer Jun 27, 2024 08:00AM
Immunome Announces Completion of Purchase of Assets from Atreca May 20, 2024 08:00AM
Immunome Inc. (IMNM) Appoints Max Rosett as CFO May 17, 2024 08:00AM
View Older Stories

May 17, 2024 08:00AM Immunome Announces Promotion of Max Rosett to Chief Financial Officer
May 14, 2024 08:00AM Immunome Reports First Quarter 2024 Financial Results and Provides Business Update
May 8, 2024 08:00AM Immunome to Present at 2024 Bank of America Healthcare Conference
May 2, 2024 08:00AM Immunome Inc. (IMNM) Appoints Kinney Horn as Chief Business Officer
May 2, 2024 08:00AM Immunome Appoints Kinney Horn as Chief Business Officer
Apr 25, 2024 08:30AM Immunome Inc. (IMNM) Appoints Sandra M. Swain to its Board
Apr 25, 2024 08:26AM Immunome Appoints Sandra M. Swain to Board of Directors
Apr 5, 2024 08:00AM Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
Mar 28, 2024 04:02PM Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
Mar 26, 2024 08:00AM Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
Mar 7, 2024 08:00AM Immunome to Participate in the Leerink Partners Global Biopharma Conference
Mar 1, 2024 08:00AM Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference
Feb 20, 2024 08:15AM Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
Feb 6, 2024 08:00AM Immunome Inc. (IMNM) To Acquire AL102
Feb 6, 2024 08:00AM Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
Feb 5, 2024 08:00AM Immunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Jan 8, 2024 07:05AM Immunome Inc. (IMNM) Exclusively Licenses Zentalis (ZNTL) ROR1 Antibody-Drug Conjugate
Jan 8, 2024 07:00AM Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
Jan 4, 2024 08:09AM Immunome (IMNM) Appoints Phil Roberts as CTO
Jan 4, 2024 08:00AM Immunome Appoints Phil Roberts as Chief Technical Officer
Jan 3, 2024 08:00AM Immunome to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Jan 2, 2024 08:02AM Immunome Inc. (IMNM) Appoints Carol A. Schafer to its Board
Jan 2, 2024 08:00AM Immunome Appoints Carol A. Schafer to Board of Directors
Dec 26, 2023 08:30AM Immunome Inc. (IMNM) to Acquire Antibody-Related Assets and Materials from Atreca (BCEL)
Dec 26, 2023 08:30AM Immunome to Acquire Antibody-Related Assets and Materials from Atreca
Nov 10, 2023 08:00AM Immunome to Present at the Stifel 2023 Healthcare Conference
Nov 9, 2023 08:00AM Immunome Reports Third Quarter 2023 Financial Results
Nov 8, 2023 08:00AM Immunome Appoints Jean-Jacques Bienaimé to Board of Directors
Oct 19, 2023 08:00AM Immunome Inc. (IMNM) Appoints Bob Lechleider as Chief Medical Officer
Oct 19, 2023 08:00AM Immunome Appoints Bob Lechleider, M.D., as Chief Medical Officer
Oct 3, 2023 08:05AM Immunome Inc. (IMNM) and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer Therapies
Oct 3, 2023 08:00AM Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer Therapies
May 23, 2023 04:07PM Immunome (IMNM) Publishes Preclinical Research Demonstrating that Inhibition of IL-38
May 23, 2023 04:05PM Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity
May 5, 2023 08:00AM Immunome Reports First Quarter 2023 Financial Results
Mar 16, 2023 08:00AM Immunome Reports Fourth Quarter and Full Year 2022 Financial Results
Mar 9, 2023 08:45AM Immunome to Present at 13th Annual World ADC London Conference
Feb 8, 2023 08:00AM Immunome Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board
Jan 6, 2023 08:02AM AbbVie (ABBV), Immunome (IMNM) Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets
Jan 6, 2023 08:00AM AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets
Jan 6, 2023 08:00AM AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets
Nov 9, 2022 12:04PM Immunome (IMNM) Presents Preclinical Data on IMM20059
Nov 9, 2022 12:00PM Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
Nov 7, 2022 08:17AM Immunome (IMNM) Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059
Nov 7, 2022 08:15AM Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
Jun 2, 2022 08:00AM Immunome to Present at the Jefferies Healthcare Conference
May 23, 2022 08:00AM Immunome Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38
May 19, 2022 08:01AM Immunome (IMNM) Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant
May 19, 2022 08:00AM Immunome Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant
Mar 11, 2022 08:00AM Immunome Inc. (IMNM) Announces FDA Lifts Clinical Hold on its IMM-BCP-01 IND Application for the Treatment of COVID-19
View Older Stories